| The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies K Bajou, V Masson, RD Gerard, PM Schmitt, V Albert, M Praus, LR Lund, ... The Journal of cell biology 152 (4), 777-784, 2001 | 418 | 2001 |
| Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia N Toft, H Birgens, J Abrahamsson, L Gri¹kevièius, H Hallböök, M Heyman, ... Leukemia 32 (3), 606-615, 2018 | 360 | 2018 |
| Functional overlap between two classes of matrix-degrading proteases in wound healing LR Lund, J Rømer, TH Bugge, BS Nielsen, TL Frandsen, JL Degen, ... The EMBO journal 18 (17), 4645-4656, 1999 | 346 | 1999 |
| MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780 N Brünner, TL Frandsen, C Holst-Hansen, M Bei, EW Thompson, ... Cancer research 53 (14), 3229-3232, 1993 | 275 | 1993 |
| Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction K Schmiegelow, SN Nielsen, TL Frandsen, J Nersting Journal of pediatric hematology/oncology 36 (7), 503-517, 2014 | 266 | 2014 |
| Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus K Schmiegelow, A Attarbaschi, S Barzilai, G Escherich, TL Frandsen, ... The Lancet Oncology 17 (6), e231-e239, 2016 | 238 | 2016 |
| MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal … N Brünner, B Boysen, S Jirus, TC Skaar, C Holst-Hansen, J Lippman, ... Cancer research 57 (16), 3486-3493, 1997 | 238 | 1997 |
| Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-basedin vitro assays SN Bae, G Arand, H Azzam, P Pavasant, J Torri, TL Frandsen, ... Breast cancer research and treatment 24, 241-255, 1993 | 166 | 1993 |
| Asparaginase‐associated pancreatitis in children RA Raja, K Schmiegelow, TL Frandsen British journal of haematology 159 (1), 18-27, 2012 | 156 | 2012 |
| 1α,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cellsin vitro CM Hansen, TL Frandsen, N Brünner, L Binderup Clinical & experimental metastasis 12, 195-202, 1994 | 126 | 1994 |
| Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study BO Wolthers, TL Frandsen, A Baruchel, A Attarbaschi, S Barzilai, ... The Lancet Oncology 18 (9), 1238-1248, 2017 | 106 | 2017 |
| Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years CU Rank, N Toft, R Tuckuviene, K Grell, OJ Nielsen, TL Frandsen, ... Blood, The Journal of the American Society of Hematology 131 (22), 2475-2484, 2018 | 103 | 2018 |
| Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia–a multicentre study from the Nordic Society of Paediatric Haematology and Oncology S Ranta, R Tuckuviene, A Mäkipernaa, BK Albertsen, T Frisk, U Tedgård, ... British journal of haematology 168 (4), 547-552, 2015 | 98 | 2015 |
| Asparaginase‐associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL 2008 protocol RA Raja, K Schmiegelow, BK Albertsen, K Prunsild, B Zeller, ... British journal of haematology 165 (1), 126-133, 2014 | 95 | 2014 |
| Hormone resistance, invasiveness, and metastatic potential in breast cancer R Clarke, EW Thompson, F Leonessa, J Lippman, M McGarvey, ... Breast cancer research and treatment 24, 227-239, 1993 | 89 | 1993 |
| Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy K Schmiegelow, K Müller, SS Mogensen, PR Mogensen, BO Wolthers, ... F1000Research 6, 2017 | 88 | 2017 |
| Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study BK Albertsen, K Grell, J Abrahamsson, B Lund, K Vettenranta, ... Journal of Clinical Oncology 37 (19), 1638-1646, 2019 | 87 | 2019 |
| Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice K Almholt, BS Nielsen, TL Frandsen, N Brünner, K Danø, M Johnsen Oncogene 22 (28), 4389-4397, 2003 | 85 | 2003 |
| Complying with the European Clinical Trials directive while surviving the administrative pressure–an alternative approach to toxicity registration in a cancer trial TL Frandsen, M Heyman, J Abrahamsson, K Vettenranta, A Åsberg, ... European journal of cancer 50 (2), 251-259, 2014 | 84 | 2014 |
| Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and … TL Frandsen, C Holst-Hansen, BS Nielsen, IJ Christensen, JR Nyengaard, ... Cancer research 61 (2), 532-537, 2001 | 77 | 2001 |
benjamin wolthersRigshospitalet, DenmarkVerified email at regionh.dk
